Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immtech progresses malaria treatment
In this trial, taking place in Thailand, patients are treated for three days with DB289, as a single therapy or in combination with the drug artesunate. Trial patients
In this trial, taking place in Thailand, patients are treated for three days with DB289, as a single therapy or in combination with the drug artesunate. Trial patients
The strategic agreement between the partners covers development of both pandemic and interpandemic (seasonal) influenza vaccines using Crucell’s proprietary PERC6 cell line technology. Clinical trials for Sanofi /
The phase I trial, which will test the safety and tolerability of single and multiple oral doses in healthy volunteers, is expected to finish in the second half
The two-year study showed that by using Applied NeuroSolutions’ test, which measures the amount of an abnormal protein, called p-tau in conjunction with current methods to diagnose Alzheimer’s,
In a breast cancer model, ENMD-1198 was shown to inhibit a protein called HIF-1alpha which is over-expressed in more than 70% of human tumors. This over-expression correlates with
The companies agreed Transgene would be paid a fixed total amount, with installments made at specified times over the life of the contract to produce the Innogenetics vaccine.
The objectives of the trial are to evaluate the safety, toxicity, pharmacokinetic profile and initial clinical activity of KP-1461. The trial is being conducted at several HIV treatment
Despite this perception, many adults aged 55 and over have one or more factors that put them at increased risk for stomach ulcers that can result from chronic
The phase II proof-of-concept study demonstrated clinically meaningful and statistically significant improvement in the primary endpoint, the international prostate symptom score (IPSS), a seven-item questionnaire that assesses the
The trial involves priming an immune response with multiple doses of a plasmid DNA vaccine, based on Vical’s proprietary DNA delivery technology, and boosting the response with a